MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Fresh2 Group Ltd

Healthcare US FRES

3.275USD
0.36(12.54%)

Last update at 2024-07-11T14:38:00Z

Day Range

3.253.27
LowHigh

52 Week Range

0.304.75
LowHigh

Fundamentals

  • Previous Close 2.91
  • Market Cap9.81M
  • Volume23379
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-115.58300M
  • Revenue TTM16.98M
  • Revenue Per Share TTM3.83
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-7.56

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -105.72800M -121.26700M -80.65300M -101.83900M
Minority interest 1.71M 1.39M 0.09M 0.56M
Net income -101.89300M -118.69500M -80.47500M -101.06000M
Selling general administrative 82.94M 102.10M 94.43M 84.41M
Selling and marketing expenses - - - -
Gross profit 8.34M 12.25M 12.88M 4.80M
Reconciled depreciation 5.50M 3.91M 3.10M 2.66M
Ebit - -106.04600M -93.12600M -87.76200M
Ebitda -99.85700M -113.10000M -79.51000M -96.56600M
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -84.13800M -106.04600M -93.12600M -89.08200M
Other operating expenses - - - 0.37M
Interest expense 0.37M 4.26M 1.14M 2.61M
Tax provision -2.13000M -1.18000M -0.08800M -0.21800M
Interest income - - - -
Net interest income -0.37300M -4.25700M -1.14300M -2.60900M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - -1.18000M -0.08800M -0.21800M
Total revenue 12.04M 17.99M 20.51M 10.85M
Total operating expenses 96.18M 124.03M 113.64M 99.93M
Cost of revenue 3.71M 5.73M 7.63M 6.05M
Total other income expense net -21.21700M -10.96400M 13.62M -10.14800M
Discontinued operations - - - -
Net income from continuing ops -103.59800M -120.08700M -80.56500M -101.62100M
Net income applicable to common shares - -118.69500M -80.47500M -101.06000M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 40.47M 67.49M 49.89M 52.98M
Intangible assets 1.30M 9.99M 5.76M 6.39M
Earning assets - - - -
Other current assets 3.74M 4.70M 5.59M 12.31M
Total liab 49.87M 66.17M 46.61M 68.91M
Total stockholder equity -13.67600M -4.49900M 2.95M -15.97300M
Deferred long term liab - - - -
Other current liab 9.53M 7.54M 6.04M 5.65M
Common stock - 1.28M 0.81M 0.66M
Capital stock 5.73M 1.28M 0.81M 0.66M
Retained earnings -577.53900M -475.64600M -356.95100M -276.47600M
Other liab - 3.27M 3.09M 2.71M
Good will 0.00000M 12.76M 2.22M 2.22M
Other assets - - 0.46M 1.00M
Cash 1.87M 9.25M 3.02M 6.12M
Cash and equivalents - - - -
Total current liabilities 42.28M 62.91M 43.52M 66.20M
Current deferred revenue - - - -
Net debt 3.15M 24.51M 5.22M 32.44M
Short term debt - - - -
Short long term debt 5.01M 33.76M 8.23M 38.57M
Short long term debt total - - - -
Other stockholder equity - 4.53M 4.79M 2.11M
Property plant equipment - 20.26M 19.27M 18.87M
Total current assets 13.70M 23.55M 21.29M 22.17M
Long term investments 1.08M 0.92M 0.88M 2.33M
Net tangible assets - -27.25200M -5.03700M -24.59000M
Short term investments - - - -
Net receivables 6.12M 7.61M 10.62M 3.42M
Long term debt - - - -
Inventory 0.21M 0.49M 0.31M 0.31M
Accounts payable 2.11M 2.73M 2.13M 1.80M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - 0.46M 1.00M
Deferred long term asset charges - - - -
Non current assets total 26.77M 43.94M 28.60M 30.81M
Capital lease obligations 7.30M - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.59200M -3.93200M -2.48200M -0.30000M
Change to liabilities 0.00000M 0.47M 1.49M -1.76900M
Total cashflows from investing activities - -3.93200M -2.48200M -3.46100M
Net borrowings - 38.46M -24.50300M 5.85M
Total cash from financing activities 49.47M 83.42M 60.92M 46.11M
Change to operating activities - -3.09400M 7.83M 5.67M
Net income -101.89300M -118.69500M -80.47500M -101.06000M
Change in cash -7.38100M 6.24M -3.10900M -6.76200M
Begin period cash flow 9.25M 3.02M 6.12M 12.89M
End period cash flow 1.87M 9.25M 3.02M 6.12M
Total cash from operating activities -55.06000M -71.70900M -58.96700M -48.60000M
Issuance of capital stock 61.01M 42.35M 110.67M 47.60M
Depreciation 5.47M 3.88M 3.07M 2.64M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory 0.28M -0.18000M -0.04400M 1.16M
Change to account receivables 2.90M 1.54M -7.25600M 1.29M
Sale purchase of stock -11.00300M - -25.61900M 0.00000M
Other cashflows from financing activities - - -25.24900M -7.34400M
Change to netincome - 44.34M 16.39M 43.45M
Capital expenditures 1.59M 3.90M 2.47M 2.79M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 8.67M -1.26800M 2.02M 6.35M
Stock based compensation 14.92M 34.17M 17.76M 32.85M
Other non cash items -0.14400M 9.07M 3.24M 5.30M
Free cash flow -56.65200M -75.68200M -61.45900M -51.76100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FRES
Fresh2 Group Ltd
0.36 12.54% 3.27 - - 0.54 0.71 0.54 -0.0694
NVO
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

Profile

Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. Further, it operates an e-commerce platform that connects food suppliers and supermarket operators and restaurant owners. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is based in New York, New York.

Fresh2 Group Ltd

650 5th Ave, New York, NY, United States, 10019-6108

Key Executives

Name Title Year Born
Mr. Haohan Xu Chairman of the Board & CEO 1995
Dr. He Yu Co-Founder & Chief Scientist 1958
Ms. Xiaoyu Li Director & CFO 1989
Mr. Weidong Dai China President 1961
Dr. Sunil Pandit U.S. Chief Executive Officer NA
Mr. Yidong Hu Chief Strategy Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.